SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Iovance Biotherapeutics filed an 8-K to update its corporate…

IOVANCE BIOTHERAPEUTICS, INC. · 8-K filed Jul 2, 2026 at 17:01 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jul 2, 2026 at 17:01 ET

Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine administrative event. The presentation reiterates previously disclosed financial guidance (FY26 revenue $350M-$370M, Q2 2026 revenue $86M-$88M) and pipeline progress, including the TILVANCE-301 Phase 3 frontline melanoma trial and IOV-LUN-202 NSCLC registrational trial. No new material financial data or business developments were disclosed beyond what was already public.

  • Filed 8-K to update corporate presentation used at healthcare conferences and with analysts.
  • FY26 total revenue guidance reiterated at $350M-$370M.
  • Q2 2026 revenue guidance reiterated at $86M-$88M.
  • Cash position as of 3/31/26: ~$319M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access